Publication: Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer.
Loading...
Identifiers
Publication date
Advisors
Journal Title
Journal ISSN
Volume Title
Publishers
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease for which better therapies are urgently needed. Fibroblasts and macrophages are heterogeneous cell populations able to enhance metastasis, but the role of a macrophage-fibroblast crosstalk in regulating their pro-metastatic functions remains poorly understood. Here we deconvolve how macrophages regulate metastasis-associated fibroblast (MAF) heterogeneity in the liver. We identify three functionally distinct MAF populations, among which the generation of pro-metastatic and immunoregulatory myofibroblastic-MAFs (myMAFs) critically depends on macrophages. Mechanistically, myMAFs are induced through a STAT3-dependent mechanism driven by macrophage-derived progranulin and cancer cell-secreted leukaemia inhibitory factor (LIF). In a reciprocal manner, myMAF secreted osteopontin promotes an immunosuppressive macrophage phenotype resulting in the inhibition of cytotoxic T cell functions. Pharmacological blockade of STAT3 or myMAF-specific genetic depletion of STAT3 restores an anti-tumour immune response and reduces metastases. Our findings provide molecular insights into the complex macrophage-fibroblast interactions in tumours and reveal potential targets to inhibit PDAC liver metastasis.
Description
We thank the Liverpool Shared Research Facilities including the Centre for Cellular imaging (CCI), Centre for Genomic Research (CGR), Computational Biology Facility (CBF), Cell Sorting Facility (CSF), and the Biomedical Services Unit (BSU) for provision of equipment and technical assistance. We thank Elzbieta Boyd for the generation of reagents. We thank Ruth Stafferton for consenting of patients. We thank the patients and their families who contributed with tissue samples to these studies. We thank both Professor Scott Friedman for agreeing to share the LX2 cell line, and Professor Jelena Mann for donation of the LX2 cell line. These studies were supported by grants from Cancer Research UK (A25607, A26978, A26979), Medical Research Council (MR/P018920/1) and North West Cancer Research Fund for M.C.S, Wellcome Trust (102521/Z/13/Z) and North West Cancer Research Funds for A.M., Cancer Research UK A17196, A2996, and A25233 for J.P.M. N.C.H. is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (ref. 219542/Z/19/Z).
MeSH Terms
DeCS Terms
Bibliographic citation
Nat Commun . 2024 Apr 27;15(1):3593.





